Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy
Lu Y, Huntoon K, Lee D, Wang Y, Ha J, Qie Y, Li X, Schrank B, Dong S, Gallup T, Kang M, Zhao H, An Y, Yang Z, Li J, Kim B, Jiang W. Immunological conversion of solid tumours using a bispecific nanobioconjugate for cancer immunotherapy. Nature Nanotechnology 2022, 17: 1332-1341. PMID: 36357792, PMCID: PMC10036139, DOI: 10.1038/s41565-022-01245-7.Peer-Reviewed Original ResearchConceptsInnate immune cellsSolid tumorsImmune cellsEffectiveness of immunotherapyImmune checkpoint blockadeCancer cellsImmune regulatory moleculesHigh response rateCyclic guanosine monophosphate-adenosine monophosphate synthaseBlood cancer cellsInterferon genes (STING) pathwayCheckpoint blockadeCancer immunotherapyHaematological malignanciesImmunotherapyResponse rateTumorsBiological disparitiesLimited responseMember 7Haematologic tumoursDifferential expressionCellsRegulatory moleculesGene pathways